Drug company’s hearing too sensitive for criticism When companies can use the courts to prevent concerned citizens from criticising their products, its time for legal reforms to
Is nanotechnology rushing into a repeat of the biotechnology backlash? Risks associated with the science of the small demand a Government commitment to protect the public interest, writes Georgia Miller
What’s wrong with pushing pills? Erectile dysfunction? Menopause? Pop a pill! By persuading consumers to buy more drugs, whether or not they need them, drug
Genuine Progress? Part One Nicholas Gruen likes the Australia Institute’s attempt to create a broader measure of economic wellbeing but is disappointed by the
The Mysterious Money Machine After a week where rates have held our interest, Steve Keen lends a hand to those baffled by our monetary
Drug companies’ free lunches have expensive side-effects It may only take an apple a day to keep the doctors away – but should it really take a
A Health Policy for Australia’: response #4 Tim Woodruff of the Doctors Reform Society argues that the fee for service contribution to the inappropriate use of health
A Health Policy for Australia’: response #3 Don Hindle likes the proposal for a single health insurance scheme but says that user payments are ‘a dumb idea
Spend or cut: ALP can’t have it both ways Tristan Ewins wonders how an ALP government could afford to fund its ‘nation building’ programs if Kim Beazley’s promised tax
